T. Ian Clark's most recent trade in Olema Pharmaceuticals Inc was a trade of 209,690 Common Stock done at an average price of $4.4 . Disclosure was reported to the exchange on Dec. 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Olema Pharma Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.41 per share. | 19 Dec 2025 | 209,690 | 209,690 | - | 4.4 | 923,894 | Common Stock |
| Olema Pharma Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2025 | 209,690 | 0 | - | - | Stock Option (Right to Buy) | |
| Olema Pharma Inc | Ian T. Clark | Director | Sale of securities on an exchange or to another person at price $ 29.71 per share. | 19 Dec 2025 | 193,056 | 41,840 | - | 29.7 | 5,735,694 | Common Stock |
| Olema Pharma Inc | Ian T. Clark | Director | Sale of securities on an exchange or to another person at price $ 30.48 per share. | 19 Dec 2025 | 41,840 | 0 | - | 30.5 | 1,275,283 | Common Stock |
| Olema Pharma Inc | Ian T. Clark | Director | Sale of securities on an exchange or to another person at price $ 28.83 per share. | 19 Dec 2025 | 29,904 | 234,896 | - | 28.8 | 862,132 | Common Stock |
| Olema Pharma Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2025 | 21,520 | 0 | - | - | Stock Option (Right to Buy) | |
| Olema Pharma Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2025 | 21,520 | 0 | - | - | Stock Option (Right to Buy) | |
| Olema Pharma Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.84 per share. | 19 Dec 2025 | 21,520 | 252,730 | - | 7.8 | 168,717 | Common Stock |
| Olema Pharma Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.61 per share. | 19 Dec 2025 | 21,520 | 231,210 | - | 3.6 | 77,687 | Common Stock |
| Olema Pharma Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2025 | 12,070 | 12,080 | - | - | Stock Option (Right to Buy) | |
| Olema Pharma Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.08 per share. | 19 Dec 2025 | 12,070 | 264,800 | - | 4.1 | 49,246 | Common Stock |
| Guardant Health Inc | Ian T. Clark | Director | Sale of securities on an exchange or to another person at price $ 107.27 per share. | 05 Dec 2025 | 17,055 | 13,251 (0%) | 0% | 107.3 | 1,829,495 | Common Stock |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2025 | 10,703 | 0 | - | - | Stock Option (Right to Buy) | |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.84 per share. | 05 Dec 2025 | 10,703 | 38,462 (0%) | 0% | 31.8 | 340,784 | Common Stock |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.42 per share. | 05 Dec 2025 | 9,105 | 18,956 (0%) | 0% | 38.4 | 349,814 | Common Stock |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2025 | 9,105 | 0 | - | - | Stock Option (Right to Buy) | |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2025 | 8,803 | 0 | - | - | Stock Option (Right to Buy) | |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.00 per share. | 05 Dec 2025 | 8,803 | 27,759 (0%) | 0% | 38.0 | 334,558 | Common Stock |
| Guardant Health Inc | Ian T. Clark | Director | Sale of securities on an exchange or to another person at price $ 106.67 per share. | 05 Dec 2025 | 8,156 | 30,306 (0%) | 0% | 106.7 | 869,968 | Common Stock |
| Guardant Health Inc | Ian T. Clark | Director | Sale of securities on an exchange or to another person at price $ 108.05 per share. | 05 Dec 2025 | 3,400 | 9,851 (0%) | 0% | 108.0 | 367,354 | Common Stock |
| Biomarin pharma Inc - Registered Shares | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2025 | 7,000 | 7,000 (0%) | 0% | 0 | Common Stock | |
| GoodRx Holdings Inc (Class A) | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2025 | 17,248 | 34,497 | - | - | Restricted Stock Unit | |
| GoodRx Holdings Inc (Class A) | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.74 per share. | 08 Jul 2025 | 17,248 | 100,150 | - | 4.7 | 81,756 | Class A Common Stock |
| Guardant Health Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 6,833 | 6,833 | - | - | Stock Option (Right to Buy) | |
| Guardant Health Inc | Ian T. Clark | Director | Sale of securities on an exchange or to another person at price $ 48.38 per share. | 17 Jun 2025 | 6,672 | 9,851 (0%) | 0% | 48.4 | 322,819 | Common Stock |
| Guardant Health Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 5,092 | 5,092 | - | - | Restricted Stock Units | |
| Corvus Pharma Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2025 | 8,088 | 16,523 (0%) | 0% | 0 | Common Stock | |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2025 | 8,088 | 0 | - | - | Restricted Stock Units | |
| Olema Pharma Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 24,150 | 24,150 | - | - | Stock Option (right to buy) | |
| GoodRx Holdings Inc (Class A) | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 57,050 | 82,902 | - | 0 | Class A Common Stock | |
| Kyverna Therapeutics Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 65,351 | 65,351 | - | - | Stock Option (right to buy) | |
| Kyverna Therapeutics Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 16,634 | 16,634 | - | 0 | Common Stock | |
| Altria Group | Ian L.T. Clarke | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 3,219 | 15,094 (0%) | 0% | 0 | Common Stock | |
| Guardant Health Inc | Ian T. Clark | Director | Other type of transaction at price $ 0.00 per share. | 12 Nov 2024 | 8,435 | 0 (0%) | 0% | 0 | Common Stock | |
| Guardant Health Inc | Ian T. Clark | Director | Other type of transaction at price $ 0.00 per share. | 12 Nov 2024 | 8,435 | 8,435 (0%) | 0% | 0 | Common Stock | |
| Guardant Health Inc | Ian T. Clark | Director | Sale of securities on an exchange or to another person at price $ 29.44 per share. | 12 Nov 2024 | 7,242 | 8,435 (0%) | 0% | 29.4 | 213,169 | Common Stock |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2024 | 1,076 | 0 | - | - | Stock Option (Right to Buy) | |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.18 per share. | 12 Nov 2024 | 1,076 | 16,753 (0%) | 0% | 4.2 | 4,498 | Common Stock |
| Guardant Health Inc | Ian T. Clark | Director | Sale of securities on an exchange or to another person at price $ 29.52 per share. | 12 Nov 2024 | 1,076 | 15,677 (0%) | 0% | 29.5 | 31,761 | Common Stock |
| GoodRx Holdings Inc (Class A) | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2024 | 51,745 | 51,745 | - | - | Restricted Stock Unit | |
| GoodRx Holdings Inc (Class A) | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2024 | 25,852 | 25,852 | - | 0 | Class A Common Stock | |
| Olema Pharma Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 23,000 | 23,000 | - | - | Stock Option (right to buy) | |
| Corvus Pharma Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Guardant Health Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 10,703 | 10,703 | - | - | Stock Option (Right to Buy) | |
| Guardant Health Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 8,088 | 8,088 | - | - | Restricted Stock Units | |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 6,776 | 15,677 (0%) | 0% | 0 | Common Stock | |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 6,776 | 0 | - | - | Restricted Stock Units | |
| Altria Group | Ian L.T. Clarke | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 3,800 | 11,225 (0%) | 0% | 0 | Common Stock | |
| Corvus Pharma Inc | T. Ian Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Altria Group | Ian L.T. Clarke | Director | Purchase of securities on an exchange or from another person at price $ 40.57 per share. | 06 Nov 2023 | 1,100 | 7,145 (0%) | 0% | 40.6 | 44,625 | Common Stock |
| Olema Pharma Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | |
| Corvus Pharma Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Guardant Health Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 8,803 | 8,803 | - | - | STOCK OPTION (RIGHT TO BUY) | |
| Guardant Health Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 6,776 | 6,776 | - | - | RESTRICTED STOCK UNITS | |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2023 | 6,703 | 8,901 (0%) | 0% | 0 | COMMON STOCK | |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2023 | 6,703 | 0 | - | - | RESTRICTED STOCK UNITS | |
| Tectonic Therapeutic Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 17,643 | 17,643 | - | - | Stock Option (Right to Buy) | |
| Altria Group | Ian L.T. Clarke | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 3,901 | 5,964 (0%) | 0% | 0 | Common Stock | |
| Corvus Pharma Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Olema Pharma Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | |
| Corvus Pharma Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Guardant Health Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 8,789 | 8,789 | - | - | STOCK OPTION (RIGHT TO BUY) | |
| Guardant Health Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 6,703 | 6,703 | - | - | RESTRICTED STOCK UNITS | |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2022 | 2,198 | 0 | - | - | RESTRICTED STOCK UNITS | |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2022 | 2,198 | 2,198 (0%) | 0% | 0 | COMMON STOCK | |
| Tectonic Therapeutic Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 17,478 | 17,478 | - | - | Stock Option (Right to Buy) | |
| Tectonic Therapeutic Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 17,478 | 17,478 | - | - | Stock Option (Right to Buy) | |
| Agios Pharma Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 0 | - | - | Restricted stock unit | |
| Agios Pharma Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 6,549 (0%) | 0% | 0 | Common stock | |
| Altria Group | Ian L.T. Clarke | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 3,372 | 3,372 (0%) | 0% | 0 | Common Stock | |
| Altria Group | Ian L.T. Clarke | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.90 per share. | 19 May 2022 | 1,309 | 2,063 (0%) | 0% | 51.9 | 67,937 | Common Stock |
| Corvus Pharma Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2021 | 1,076 | 1,076 | - | - | STOCK OPTION (RIGHT TO BUY) | |
| Guardant Health Inc | Ian T. Clark | Director | Sale of securities on an exchange or to another person at price $ 130.00 per share. | 01 Sep 2021 | 1,076 | 0 (0%) | 0% | 130 | 139,880 | COMMON STOCK |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.18 per share. | 01 Sep 2021 | 1,076 | 1,076 (0%) | 0% | 4.2 | 4,498 | COMMON STOCK |
| Guardant Health Inc | Ian T. Clark | Director | Sale of securities on an exchange or to another person at price $ 130.00 per share. | 29 Jun 2021 | 10,559 | 0 (0%) | 0% | 130 | 1,372,670 | COMMON STOCK |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 77.09 per share. | 29 Jun 2021 | 4,840 | 10,559 (0%) | 0% | 77.1 | 373,116 | COMMON STOCK |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2021 | 4,840 | 0 | - | - | STOCK OPTION (RIGHT TO BUY) | |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2021 | 1,076 | 2,152 | - | - | STOCK OPTION (RIGHT TO BUY) | |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.18 per share. | 29 Jun 2021 | 1,076 | 5,719 (0%) | 0% | 4.2 | 4,498 | COMMON STOCK |
| Guardant Health Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 3,135 | 3,135 | - | - | STOCK OPTION (RIGHT TO BUY) | |
| Guardant Health Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 2,198 | 2,198 | - | - | RESTRICTED STOCK UNITS | |
| Tectonic Therapeutic Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 17,438 | 17,438 | - | - | Stock Option (Right to Buy) | |
| Olema Pharma Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 21,520 | 21,520 | - | - | Stock Option (right to buy) | |
| Agios Pharma Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 1,686 | 4,964 (0%) | 0% | 0 | Common stock | |
| Agios Pharma Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 1,686 | 0 | - | - | Restricted stock units | |
| Agios Pharma Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 8,888 | 8,888 | - | - | Stock options (right to buy) | |
| Agios Pharma Inc | Ian T. Clark | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 1,585 | 1,585 | - | - | Restricted stock unit | |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2021 | 538 | 3,228 | - | - | STOCK OPTION (RIGHT TO BUY) | |
| Guardant Health Inc | Ian T. Clark | Director | Sale of securities on an exchange or to another person at price $ 159.92 per share. | 26 Apr 2021 | 538 | 4,643 (0%) | 0% | 159.9 | 86,037 | COMMON STOCK |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.18 per share. | 26 Apr 2021 | 538 | 5,181 (0%) | 0% | 4.2 | 2,249 | COMMON STOCK |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2021 | 538 | 3,766 | - | - | STOCK OPTION (RIGHT TO BUY) | |
| Guardant Health Inc | Ian T. Clark | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.18 per share. | 25 Mar 2021 | 538 | 5,181 (0%) | 0% | 4.2 | 2,249 | COMMON STOCK |
| Guardant Health Inc | Ian T. Clark | Director | Sale of securities on an exchange or to another person at price $ 132.09 per share. | 25 Mar 2021 | 538 | 4,643 (0%) | 0% | 132.1 | 71,064 | COMMON STOCK |